ArticleJournal of clinical microbiology1993
Circulating Candida antigens and antibodies: useful markers of candidemia.
Article in Journal of clinical microbiology, 1993. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 47 citations in OpenAlex.
- A prospective randomized controlled trial comparing PCR-based and empirical treatment with liposomal amphotericin B in patients after allo-SCT.Bone marrow transplantation · 2009Trial
- Trial
- Agglutination of yeast-binding antibodies from human blood plasma products.BMC microbiology · 2025Article
- Biomarker-guided antifungal stewardship policies for patients with invasive candidiasis.Current medical mycology · 2018Review
- Application of Culture-Independent Rapid Diagnostic Tests in the Management of Invasive Candidiasis and Cryptococcosis.Journal of fungi (Basel, Switzerland) · 2015Review
- Immunoglobulin G responses to a panel of Candida albicans antigens as accurate and early markers for the presence of systemic candidiasis.Journal of clinical microbiology · 2008Article
- Urinary D-arabinitol/L-arabinitol levels in infants undergoing long-term antibiotic therapy.Journal of clinical microbiology · 2005Article
- Circulating beta (1-3) glucan and immunoglobulin G subclass antibodies to Candida albicans cell wall antigens in patients with systemic candidiasis.Clinical and diagnostic laboratory immunology · 2004Article
- The cell wall-associated glyceraldehyde-3-phosphate dehydrogenase of Candida albicans is also a fibronectin and laminin binding protein.Infection and immunity · 1998Article
- Cell wall and secreted proteins of Candida albicans: identification, function, and expression.Microbiology and molecular biology reviews : MMBR · 1998Review
- Serologic response to cell wall mannoproteins and proteins of Candida albicans.Clinical microbiology reviews · 1998Review
- The glycolytic enzyme glyceraldehyde-3-phosphate dehydrogenase of Candida albicans is a surface antigen.Journal of bacteriology · 1997Article
- Clearances of Candida albicans-derived alpha- and beta-linked mannose residues in sera from patients with candidiasis.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 1997Article
- Clinical and laboratory diagnosis of invasive candida infection in neutropenic patients.Medical oncology (Northwood, London, England) · 1996Review
- Genetic organization and mRNA expression of enolase genes of Candida albicans.Journal of bacteriology · 1995Article
- D-arabinitol versus mannan antigen and candidal protein antigen as a serum marker for Candida pyelonephritis.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 1995Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To investigate the utility of the 48-kDa antigen from Candida albicans in its commercial form (Directigen; Becton Dickinson) and three other serodiagnostic methods (detection of one antigen by Pastorex Candida [Sanofi Diagnostics Pasteur] and detection of immunoglobulin G [IgG] and IgM antibodies to C. albicans blastoconidia [bioMerieux]) for diagnosis of invasive Candida infection, we conducted a prospective clinical trial among 10 patients with candidemia (group 1), 30 patients colonized by C. albicans (group 2), 20 patients with bacteremia (group 3), and 20 subjects without clinical or microbiological evidence of infection. The Directigen system was positive for at least one serum sample each from eight patients in group 1. In groups 2, 3, and 4, it was positive for only three patients. There was no reaction to the Pastorex system in any of the patients infected with or colonized by C. albicans or in the non-Candida-carrying controls. The IgG antibody concentration oscillated between 100 and 800 (mean, 510 +/- 268) IU/ml for the patients in group 1. In this group, eight patients had IgG antibody levels of > 400 IU/ml. The percentages of persons with IgG antibody levels of > 400 IU/ml in groups 2, 3, and 4 were 43.3, 0, and 0, respectively. Specific IgM antibody was present in all group 1 patients but not in those in groups 2, 3, and 4. The sensitivity and specificity of the Directigen test were 65 and 97.1%, respectively. For the Pastorex test, the sensitivity was 0%. The sensitivity of IgG antibodies was 80%, with a specificity of 81.4%, while the IgM antibodies were 100% specific and sensitive. Both the positive and negative predictive values of specific IgM antibodies appeared to be superior to those of the other three tests.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.